Induction chemotherapy with nedaplatin with 5-FU Followed by intensity-modulated radiotherapy concurrent with chemotherapy for locoregionally advanced nasopharyngeal carcinoma

Japanese Journal of Clinical Oncology

Volumn 40, Issue 5, 2010, Pages 425-431

  Zheng, Jijun ^a   Wang, Ge ^a   Yang, Gary Y ^b   Wang, Daoyuan ^a   Luo, Xizhong ^a   Chen, Chuan ^a   Zhang, Zhimin ^a   Li, Qiong ^a   Xu, Wen ^a   Li, Zengpeng ^a   Wang, Dong ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Chemo Phase II; Head and neck; Radiation oncology

Indexed keywords

FLUOROURACIL; NEDAPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; FEMALE; FOLLOW UP; HEARING IMPAIRMENT; HEMATOLOGIC DISEASE; HUMAN; HYPOTHYROIDISM; INTENSITY MODULATED RADIATION THERAPY; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTITIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RADIATION RESPONSE; SIDE EFFECT; SKIN DISEASE; THROMBOCYTOPENIA; TINNITUS; VOMITING; WEIGHT REDUCTION; XEROSTOMIA; ADJUVANT THERAPY; CHINA; MIDDLE AGED; NASOPHARYNX TUMOR; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHINA; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; RADIOTHERAPY, INTENSITY-MODULATED; SURVIVAL ANALYSIS;

EID: 77952559137     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp183     Document Type: Article

References (33)

1. Yu MC. Diet and nasopharyngeal carcinoma. FEMS Microbiol Immunol 1990;2:235-42.
2. Baujat B, Audry H, Bourhis J, Chan AT, Onat H, Chua DT, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 2006;64:47-56.
3. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:1310-7.
4. Chen Y, Liu MZ, Liang SB, Zong JF, Mao YP, Tang LL, et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of China. Int J Radiat Oncol Biol Phys 2008;71:1356-64.
5. Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005;23:6730-8.
6. Adelstein DJ, Li Y, Adams GL, Wagner H, Jr, Kish JA, Ensley JF, Jr, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-8.
7. Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer 2003;97:2880-6.
8. Sasaki Y, Tamura T, Eguchi K, Shinkai T, Fujiwara Y, Fukuda M, et al. Pharmacokinetics of (glycolate-0, 00)-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin. Cancer Chemother Pharmacol 1989;23:243-6.
9. Sasaki Y, Amano T, Morita M, Shinkai T, Eguchi K, Tamura T, et al. Phase I study and pharmacological analysis of cisdiammine (glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion. Cancer Res 1991;51:1472-7.
10. Kurita H, Yamamoto E, Nozaki S, Wada S, Furuta I, Kurashina K. Multicenter phase I trial of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma. Oral Oncol 2004;40:1000-6.
11. Hirabayashi K, Okada E. Combination chemotherapy with 254-S, ifosfamide, and peplomycin for advanced or recurrent cervical cancer. Cancer 1993;71:2769-75.
12. Kato H, Fukuchi M, Manda R, Nakajima M, Miyazaki T, Sohda M, et al. Efficacy and toxicity of nedaplatin and 5-FU with radiation treatment for advanced esophageal carcinomas. Anticancer Res 2003;23:3493-8.
13. Takeda Y, Kasai H, Uchida N, Yoshida H, Maekawa R, Sugita K, et al. Enhanced antitumor efficacy of nedaplatin with 5-fluorouracil against human squamous carcinoma xenografts. Anticancer Res 1999;19: 4059-64.
14. Uchida N, Takeda Y, Hojo K, Maekawa R, Sugita K, Yoshioka T. Sequence-dependent antitumour efficacy of combination chemotherapy of nedaplatin, a novel platinum complex, with 5-fluorouracil in an in vivo murine tumour model. Eur J Cancer 1998;34:1796-801.
15. Fuwa N, Kodaira T, Kamata M, Matsumoto A, Furutani K, Tachibana H, et al. Phase I study of combination chemotherapy with 5-fluorouracil (5-FU) and nedaplatin (NDP): adverse effects and recommended dose of NDP administered after 5-FU. Am J Clin Oncol 2002;25:565-9.
16. Nutting C, Dearnaley DP, Webb S. Intensity-modulated radiation therapy: a clinical review. Br J Radiol 2000;73:459-69.
17. Xia P, Fu KK, Wong GW, Akazawa C, Verhey LJ. Comparison of treatment plans involving intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2000;48:329-37.
18. Kam MK, Chau RM, Suen J, Choi PH, Teo PM. Intensity-modulated radiotherapy in nasopharyngeal carcinoma: dosimetric advantage over conventional plans and feasibility of dose escalation. Int J Radiat Oncol Biol Phys 2003;56:145-57.
19. Rischin D, Corry J, Smith J, Stewart J, Hughes P, Peters L. Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation. J Clin Oncol 2002;20:1845-52.
20. Oh JL, Vokes EE, Kies MS, Mittal BB, Witt ME, Weichselbaum RR, et al. Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. Ann Oncol 2003;14:564-9.
21. Al-Amro A, Al-Rajhi N, Khafaga Y, Memon M, Al-Hebshi A, El-Enbabi A, et al. Neoadjuvant chemotherapy followed by concurrent chemo-radiation therapy in locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2005;62:508-13.
22. American Joint Committee on Cancer: Manual for Staging of Cancer. 5th edn. Philadelphia, PA: JB Lippincott 1997.
23. Liu WS, Su MC, Wu MF, Tseng HC, Kuo HC. Nasopharyngeal carcinoma treated with precision-oriented radiation therapy techniques including intensity-modulated radiotherapy: preliminary results. Kaohsiung J Med Sci 2004;20:49-55.
24. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
25. LeeN, XiaP, QuiveyJM, SultanemK, PoonI, AkazawaC, etal. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 2002;53:12-22.
26. Wolden SL, Chen WC, Pfister DG, Kraus DH, Berry SL, Zelefsky MJ. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys 2006;64:57-62.
27. Kam MK, Teo PM, Chau RM, Cheung KY, Choi PH, Kwan WH, et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. Int J Radiat Oncol Biol Phys 2004;60:1440-50.
28. Hong RL, Ting LL, Ko JY, Hsu MM, Sheen TS, Lou PJ, et al. Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 2001;19:4305-13.
29. Chan AT, Ma BB, Lo YM, Leung SF, Kwan WH, Hui EP, et al. Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA. J Clin Oncol 2004;22:3053-60.
30. Ferrari D, Chiesa F, Codecà C, Calabrese L, Jereczek-Fossa BA, Alterio D, et al. Locoregionally advanced nasopharyngeal carcinoma: induction chemotherapy with cisplatin and 5-fluorouracil followed by radiotherapy and concurrent cisplatin: a phase II study. Oncology 2008;74:158-166.
31. al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 1997;15:277-84.
32. Desoize B, Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol 2002;42:317-35.
33. Kawai Y, Taniuchi S, Okahara S, Nakamura M, Gemba M. Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation. Biol Pharm Bull 2005;28:1385-8.